In vivo, multimodal imaging of B cell distribution and response to antibody immunotherapy in mice

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Thorek, Daniel L J ^a   Tsao, Patricia Y ^b   Arora, Vaishali ^b   Zhou, Lanlan ^a   Eisenberg, Robert A ^b   Tsourkas, Andrew ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE; ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL LABELING; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FLUORESCENT ANTIBODY TECHNIQUE; HISTOLOGY; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE MEMBRANE; LYMPHOCYTE MIGRATION; MALE; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL CULTURE; FLUORESCENCE; IMMUNOLOGY; METHODOLOGY; PATHOLOGY; SPLEEN; STAINING; THREE DIMENSIONAL IMAGING; WHOLE BODY IMAGING;

MUS;

ANIMALS; ANTIBODIES; B-LYMPHOCYTES; CELLS, CULTURED; FLUORESCENCE; IMAGING, THREE-DIMENSIONAL; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED C57BL; ORGAN SPECIFICITY; SPLEEN; STAINING AND LABELING; WHOLE BODY IMAGING;

EID: 77956291223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010655     Document Type: Article

References (51)

1. Grillo-Lopez AJ, White CA, Dallaire BK, Varns CL, Shen CD, et al. (2000) Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 1: 1-9.
2. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, et al. (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83: 435-445.
3. Levine TD, Pestronk A (1999) IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 52: 1701-1704.
4. Pestronk A, Florence J, Miller T, Choksi R, Al-Lozi MT, et al. (2003) Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 74: 485-489.
5. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27: 611-615.
6. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358: 676-688.
7. Levine TD (2005) Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum 52: 601-607.
8. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, et al. (2002) Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 46: 2029-2033.
9. Leandro MJ, Edwards JC, Cambridge G (2002) Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 61: 883-888.
10. Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, et al. (2004) B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 50: 2580-2589.
11. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA (2002) An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 46: 2673-2677.
12. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, et al. (2004) Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 50: 3580-3590.
13. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54: 2793-2806.
14. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. (2004) Efficacy of B-Cell-Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis. N Engl J Med 350: 2572-2581.
15. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, et al. (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54: 1390-1400.
16. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology 66: 460-471.
17. Merrill J, Neuwelt C, Wallace D, Shanahan J, Latina sK, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the Randomized, Double-blind Phase II/III Study EXPLORER; 2008; Abstract L12.
18. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, Garrido Ed Ede R, et al. (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131.
19. Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350: 971-980.
20. Eisenberg R (2006) Targeting B cells in SLE: the experience with rituximab treatment (anti-CD20). Endocr Metab Immune Disord Drug Targets 6: 345-350.
21. Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, et al. (2008) Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 67: 1724-1731.
22. Sutter JA, Kwan-Morley J, Dunham J, Du Y-Z, Kamoun M, et al. (2008) A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): Factors associated with B lymphocyte recovery. Clinical Immunology 126: 282-290.
23. Eisenberg R (2009) Why can't we find a new treatment for SLE? J Autoimmun 32: 223-230.
24. Herschman HR (2003) Molecular imaging: looking at problems, seeing solutions. Science 302: 605-608.
25. Melder RJ, Elmaleh D, Brownell AL, Brownell GL, Jain RK (1994) A method for labeling cells for positron emission tomography (PET) studies. Journal of Immunological Methods 175: 79-87.
26. Fu G, Gascoigne NR (2009) Multiplexed labeling of samples with cell tracking dyes facilitates rapid and accurate internally controlled calcium flux measurement by flow cytometry. J Immunol Methods 350: 194-199.
27. Parish CR (1999) Fluorescent dyes for lymphocyte migration and proliferation studies. Immunol Cell Biol 77: 499-508.
28. Millington O, Zinselmeyer B, Brewer J, Garside P, Rush C (2007) Lymphocyte tracking and interactions in secondary lymphoid organs. Inflammation Research 56: 391-401.
29. Contag PR, Olomu IN, Stevenson DK, Contag CH (1998) Bioluminescent indicators in living mammals. Nat Med 4: 245-247.
30. Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, et al. (2009) Tumor burden influences exposure and response to rituximab: pharmacokineticpharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113: 3765-3772.
31. Thorek DL, Chen AK, Czupryna J, Tsourkas A (2006) Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng 34: 23-38.
32. Bulte JW, Kostura L, Mackay A, Karmarkar PV, Izbudak I, et al. (2005) Feridex-labeled mesenchymal stem cells: cellular differentiation and MR assessment in a canine myocardial infarction model. Acad Radiol 12 Suppl 1: S2-6.
33. Bulte JW (2009) In vivo MRI cell tracking: clinical studies. AJR Am J Roentgenol 193: 314-325.
34. Thorek DL, Tsourkas A (2008) Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 29: 3583-3590.
35. Tario JD, Gray BD, Wallace SS, Muirhead KA, Ohlsson-Wilhelm BM, et al. (2007) Novel Lipophilic Tracking Dyes for Monitoring Cell Proliferation. Immunological Investigations 36: 861-885.
36. Li YY, Yang Y, Bao M, Edwards CK, 3rd, Parnes JR (2006) Mouse splenic B lymphocyte activation using different activation stimuli induces in vitro splicing of tumor necrosis factor-alpha nuclear pre-mRNA. Mol Immunol 43: 613-622.
37. Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, et al. (2005) Phase II Trial of Individualized Rituximab Dosing for Patients With CD20-Positive Lymphoproliferative Disorders. J Clin Oncol 23: 1096-1102.
38. Hainsworth JD, Burris HA, III, Morrissey LH, Litchy S, Scullin DC, Jr., et al. (2000) Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 95: 3052-3056.
39. McLaughlin P, Grillo-Lopez A, Link B, Levy R, Czuczman M, et al. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16: 2825-2833.
40. Witzig TE, Vukov AM, Habermann TM, Geyer S, Kurtin PJ, et al. (2005) Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. J Clin Oncol 23: 1103-1108.
41. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, et al. (2005) Importance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy. J Immunol 174: 817-826.
42. Li Y, Chen F, Putt M, Koo YK, Madaio M, et al. (2008) B Cell Depletion with Anti-CD79 mAbs Ameliorates Autoimmune Disease in MRL/lpr Mice. J Immunol 181: 2961-2972.
43. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, et al. (2005) In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 15: 4-13.
44. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, et al. (2005) Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol 23: 1407-1413.
45. Lewin M, Carlesso N, Tung CH, Tang XW, Cory D, et al. (2000) Tat peptidederivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 18: 410-414.
46. Reichardt W, Durr C, von Elverfeldt D, Juttner E, Gerlach UV, et al. (2008) Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol 181: 4770-4779.
47. Valable S, Barbier EL, Bernaudin M, Roussel S, Segebarth C, et al. (2007) In vivo MRI tracking of exogenous monocytes/macrophages targeting brain tumors in a rat model of glioma. Neuroimage 37 Suppl 1: S47-58.
48. Bulte JW, Kraitchman DL, Mackay AM, Pittenger MF (2004) Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood 104: 3410-3412. author reply 3412-3413.
49. Chen I, Greve J, Gheysens O, Willmann J, Rodriguez-Porcel M, et al. (2009) Comparison of Optical Bioluminescence Reporter Gene and Superparamagnetic Iron Oxide MR Contrast Agent as Cell Markers for Noninvasive Imaging of Cardiac Cell Transplantation. Molecular Imaging and Biology 11: 178-187.
50. Miltenyi S, Muller W, Weichel W, Radbruch A (1990) High gradient magnetic cell separation with MACS. Cytometry 11: 231-238.
51. Koyama M, Ishihara K, Karasuyama H, Cordell J, Iwamoto A, et al. (1997) CD79 alpha/CD79 beta heterodimers are expressed on pro-B cell surfaces without associated mu heavy chain. Int Immunol 9: 1767-1772.